NASDAQ:VXRT - Vaxart Stock Price, Forecast & News

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

Vaxart Inc (NASDAQ:VXRT) posted its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.04. The biotechnology company earned $0.45 million during the quarter, compared to analysts' expectations of $0.44 million. Vaxart had a negative net margin of 222.20% and a negative return on equity of 115.71%. View Vaxart's Earnings History.

Vaxart is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Vaxart.

2 brokerages have issued 12 month price targets for Vaxart's shares. Their forecasts range from $2.00 to $6.00. On average, they expect Vaxart's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 451.7% from the stock's current price. View Analyst Price Targets for Vaxart.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaxart.

News coverage about VXRT stock has trended very positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vaxart earned a coverage optimism score of 3.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the near future. View News Stories for Vaxart.

Some companies that are related to Vaxart include Brainstorm Cell Therapeutics (BCLI), Polarityte (PTE), Surface Oncology (SURF), Pharmacyte Biotech (PMCB), BIONDVAX PHARMA/S (BVXV), Pluristem Therapeutics (PSTI), Microbot Medical (MBOT), Genocea Biosciences (GNCA), Allena Pharmaceuticals (ALNA), Curis (CRIS), INmune Bio (INMB), Idera Pharmaceuticals (IDRA), Organovo (ONVO), Neon Therapeutics (NTGN) and Entera Bio (ENTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Conatus Pharmaceuticals (CNAT), Cascadian Therapeutics (CASC), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL), Agile Therapeutics (AGRX), Fortress Biotech (FBIO), Opko Health (OPK), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Dextera Surgical (DXTR).

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $0.73.

Vaxart has a market capitalization of $34.60 million and generates $4.16 million in revenue each year. The biotechnology company earns $-18,000,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Vaxart employs 34 workers across the globe.View Additional Information About Vaxart.

The official website for Vaxart is http://www.vaxart.com/.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]